Pioneering a New Era in Immunotherapy
At Voltron Therapeutics, we are dedicated to advancing the science of immunotherapy through our revolutionary Self-Assembling Vaccine (SAV) platform. Designed to precisely target tumors and pathogens, our platform unlocks powerful, balanced immune responses while reducing development costs, risks, and timelines.
Born from cutting-edge discoveries at Massachusetts General Hospital and Harvard’s Vaccine and Immunotherapy Center, Voltron’s technology combines world-class research with real-world clinical ambition. Our goal is to deliver novel, highly efficacious treatments for patients facing cancers and infectious diseases.
The SAV Platform
Precisely target tumors and pathogens, unlocking a powerful and balanced immune responses while reducing costs, risks, and timelines.
Precision at the Core
At the heart of our innovation is the Mtb-HSP-70/Avidin fusion protein — the Modular Antigen Vehicle (MAV) — which serves as the fixed backbone of every Voltron vaccine. This modular system pairs with a broad range of biotinylated payloads (peptides, proteins, small molecules, and more) to rapidly generate powerful, targeted immunotherapies.
Our proprietary use of Mtb-HSP-70 is transformative. This unique immune stimulant:
-
Engages multiple parts of the immune system, leveraging both innate and adaptive responses.
-
Activates dendritic cells, the critical first responders in antigen presentation.
-
Increases Tumor Necrosis Factor (TNF), intensifying tumor cell death.
-
Drives a well-balanced T-cell response, activating both CD8+ cytotoxic T cells (killing cancerous/infected cells) and CD4+ helper/memory T cells (orchestrating and sustaining immune defense).
This strategic design results in broader, more durable immune responses — crucial for achieving meaningful patient outcomes in both oncology and infectious disease settings.
-
Superior Immune Activation: SAV outperforms traditional adjuvants like Alum in potency and breadth.
-
Unmatched Flexibility: Our platform enables rapid vaccine customization against emerging threats or unique tumor targets.
-
Rapid Development: Stockpiled fixed components paired with variable payloads accelerate clinical readiness.
-
Strong Safety Profile: SAV candidates have shown excellent tolerability in preclinical models, with no dose-limiting toxicities observed.
-
Robust Intellectual Property: A strong, expanding patent portfolio protects and enhances Voltron’s competitive edge.
At Voltron Therapeutics, we are reshaping the future of immunotherapy — one modular vaccine at a time. We believe in smarter science, faster solutions, and better outcomes for patients worldwide.
Join us in building a stronger immune future.